Announcements

[February 19 2018] Dandrit Biotech announces completion of the acquisition of Enochian

February 19, 2018. Los Angeles, USA – DanDrit Biotech USA, Inc. (“DanDrit”) is pleased to announce the completion of its previously reported acquisition (the “Acquisition”) of Enochian Biopharma Inc. (“Enochian”) on February 16, 2018. As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including combinatory gene therapy methods, and Enochian is now a wholly owned subsidiary of DanDrit.

Simultaneously with the acquisition, DanDrit completed a private placement to investors in the United States and a private placement to investors outside of the United States for total of 1,677,130 shares of common stock at $8.00 per share, and certain of DanDrit’s existing shareholders exercised warrants to purchase a total of 2,400,000 shares of common stock.

As consideration for the acquisition, the stockholders of Enochian received 18,081,962 shares of DanDrit’s common stock, representing 50% of DanDrit’s common stock issued and outstanding, after giving effect to the private placements, the warrant exercises and the acquisition, and expenses related to the acquisition. The stockholders of Enochian will also have the right receive pro rata shares of DanDrit's common stock upon the exercise or conversion of any of DanDrit's warrants currently outstanding.

“We are excited about DanDrit’s future and the further development of Enochian’s therapies in conjunction with DanDrit’s resources and research capabilities,” said Eric Leire, MD, DanDrit´s Chief Executive Officer. “This acquisition will not only give DanDrit access to new technology, but also bring onboard a team of bright, value-driven, experienced and enthusiastic professionals who are committed to the success of our clinical development programs.”

Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as "believes, plans" "expects" or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in DanDrit's most recent Annual Report on Form 10-K filed with the SEC and risks specific to the matters described herein, such as the consummation of the acquisition of Enochian and the success of the technology described herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and DanDrit undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

[January 17 2018] Dandrit Biotech announces acquisition of Enochian New York, NY

January 17, 2018. New York, USA – DanDrit Biotech USA, Inc. (“DanDrit”) is pleased to announce that it has signed an agreement under which it has agreed to acquire Enochian Biopharma Inc. ("Enochian") and its new technology platforms. Enochian is developing an innovative proprietary technology, which includes combinatory gene therapy methods in the field of HIV/AIDS.

DanDrit believes that through the acquisition, Enochian's technology will enhance DanDrit's research and development efforts in cellular therapy and add to its pipeline, which also includes cellular immuneoncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherapy. As consideration for the acquisition, the stockholders of Enochian shall be entitled to receive (i) 50% of the number of shares of DanDrit's common stock issued and outstanding as of the effective time of the acquisition, after giving effect to the acquisition, (ii) pro rata shares of DanDrit's common stock upon the exercise or conversion of any of DanDrit's stock options and warrants currently outstanding and (iii) expenses related to the acquisition and the transactions contemplated thereby. DanDrit plans to change its name to Enochian ImmunoScience, Inc. and to relocate to its new headquarters in Los Angeles, California.

The acquisition is subject to customary closing conditions, and in addition (i) Enochian will have executed a perpetual, sole and exclusive license with Weird Science LLC to use all of Weird Science LLC's intellectual property rights in its proprietary technology for the prevention, treatment and amelioration of HIV in humans, including an assignment of the rights to experimental studies with syngeneic and humanized mice models, and DanDrit will be satisfied with all due diligence related to such intellectual property, (ii) DanDrit, Weird Science LLC and a certain stockholder of DanDrit will have entered into an Investor Rights Agreement and a Standstill & Lock-Up Agreement, (iii) DanDrit will have not less than $19,000,000 in cash on hand, less up to a maximum of $1,000,000 of expenses related to the acquisition and (iv) DanDrit will have executed employment and/or consulting agreements with certain persons affiliated with Enochian. DanDrit expects the acquisition to be finalized on or before February 15th.

“We are excited about the potential of the Enochian technology platforms and the application of these technologies to complement ongoing research and development efforts,” said Eric Leire, MD, DanDrit´s President and Chief Executive Officer. “This acquisition demonstrates our deep commitment to continuing to invest in future innovation in the field of cellular therapy and we believe Enochian's technology will enhance our efforts to improve care for people with HIV and advanced cancers.” About DanDrit DanDrit Biotech USA, Inc. (OTCQB: DDRT) is a publicly traded, development stage, biopharmaceutical company with a 15 year history in the biotechnology industry developing immunotherapies for various types of cancer. DanDrit is currently engaged in development of innovative treatments for colon cancer.

Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as "believes, plans" "expects" or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in DanDrit's most recent Annual Report on Form 10-K filed with the SEC and risks specific to the matters described herein, such as the consummation of the acquisition of Enochian and the success of the technology described herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and DanDrit undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

[June 12 2017] DanDrit Biotech USA Inc. Announces new Therapeutic Research Strategy

June 12, 2017. New York, USA – DanDrit Biotech USA, Inc. ("DanDrit" or the "Company") is pleased to announce that on June 6, 2017, Mr. Rene Sindlev and Mr. Torben Bjørn Christensen, joined Dandrit’s Board of Directors (the "Board") as part of a new strategy to expand the Company’s focus beyond its ongoing clinical drug trials to develop new therapeutic programs to treat cancer and other serious diseases.

Read the full statement here.

[April 5 2016] DanDrit Biotech USA Inc. Announces the Purchase of Oncosynergy, Inc.

April 5, 2016. New York, USA – DanDrit Biotech USA Inc. (OTCQB: DDRT) today announced that it has entered into an agreement to acquire privately-held OncoSynergy, Inc. Based in San Francisco, OncoSynergy develops novel oncology drug candidates including the first-in-class FDA orphan drug designated anti-CD29 monoclonal antibody, OS2966. The acquisition is subject to certain conditions, among others the approval from DDRT’s shareholders.

Read the full statement here.

[September 16–17 2015] DanDrit Biotech to Present at, Cancer Vaccines Advancing Immuno-oncology

Dr. Eric Leire, CEO of DanDrit Biotech, will be a Speaker September 17 at 11:40 UK Time

Copenhagen, Denmark, September 17, 2015 - DanDrit Biotech A/S (“DanDrit Denmark”), the subsidiary of DanDrit Biotech USA, Inc. (“DanDrit”), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, announced that its Chief Executive Officer, Dr. Eiric Leire, will be speaking at the 4rth Cancer Vaccine Advancing Immuno-Oncology SMI conference at the Marriott Hotel Regents Park. 128 King Henry’s Road London.

Read the full statement here.

[September 22 2015] DanDrit Biotech A/S to Present at the Investor Day in Copenhagen Tuesday, September 22, 2015.

Dr. Eric Leire, CEO of DanDrit Biotech, will be a Speaker September 22 at 13:30 Denmark Time

Copenhagen, Denmark, September 7, 2015 - DanDrit Biotech A/S (“DanDrit Denmark”), the subsidiary of DanDrit Biotech USA, Inc. (“DanDrit”), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, announced that its Chief Executive Officer, Dr. Eiric Leire, will be speaking at the the Investor Day in Copenhagen Tuesday, September 22, 2015 at the at the Radisson Blu Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S.

Dr.Leire noted, “This is an excellent opportunity to introduce the exciting developments ongoing at DanDrit as we pursue the development of our lead compound MCV, a colorectal cancer immunotherapy.

Our proprietary and patented approach using a patient’s own blood to develop a vaccine shows great promise and we will be making several announcements shortly discussing our continuing success.”

Read the full statement here.

[July 17 2015] DanDrit Biotech Analyst Coverage Initiated: Report Issued by Nordic Bio Investor.

Click here to download the full report. There is no cost obligation to view this report. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This report is written and authored by Peter Aabo, research analyst.

[May 19–20 2015] DanDrit Biotech to Present at the 5th Annual Outsourcing in Clinical Trials Europe 2015

Read the full statement here.

[April 28 2015] DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation

Read the full press release online or as .pdf.

[April 23 2015] DanDrit Biotech and Riyadh Pharma Sign Partnership Agreement

Read the full press release online or as .pdf.

Read our full press release in Danish here.

[April 8 2015] Article in International Pharmaceutical Industry

Download it here.

[March 20 2015] Presentation from Investordagen

DanDrit CEO Eric Leire presented at the Danish Shareholders Association’s 17th Annual Investordagen.

Those interested can view the video of the presentation here and download the slides here.

[March 18 2015] Danish Shareholders Association’s 17th Annual Investordagen

Copenhagen, Denmark, February 26, 2015 – DanDrit Biotech (“DanDrit”) (OTCQB: DDRT) today informs that on March 18, 2015 at 3:00 PM, the company will present at the Danish Shareholders Association’s InvestorDagen in Copenhagen.

At the conference, Dr. Eric Leire, CEO of DanDrit, will meet with and present to investors, providing an update on the company’s most recent achievements, including VIVA the phase III clinical trial.

For the 17th consecutive year, the Danish Shareholders Association organizes the largest event for private investors. The conference is a unique opportunity to meet a wide range of independent advisors, listed companies and financial service providers that can give insights into biotechnology investment. This year’s fair will be held Wednesday, March 18, 2015 at the Radisson Blu Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S. DanDrit Biotech will present at 3:00 PM CET.

[March 3–4 2015] The 8th Annual European Life Sciences CEO Forum

Copenhagen, Denmark, February 24, 2015 - DanDrit Biotech A/S (“DanDrit Denmark”) (OTC: DDRT), the subsidiary of DanDrit Biotech USA, Inc. (“DanDrit”), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, announced that its Chief Executive Officer, Dr. Eric Leire, will be speaking at the 8th Annual European Life Sciences CEO Forum in Zurich Switzerland at the Hilton Airport Hotel, March 3–4.

Dr. Leire noted, “This is an excellent opportunity to introduce the exciting developments ongoing at DanDrit as we pursue the development of our lead compound MCV, a colorectal cancer immunotherapy. Our proprietary and patented approach using a patient’s own blood to develop a vaccine shows great promise and we will be making several announcements shortly discussing our continuing success.”

[January 21 2015] “Estonian Company Begins Production of Treatment to Cure Colorectal Cancer”

“Cellin Technologies LLC ‒ a GMP cell therapy products manufacturing company located in Tallinn, Estonia ‒ this week started production of melanoma cell lysate, the critical raw material required for the manufacture of MelCancerVac, the colorectal cancer vaccine developed by DanDrit Biotech.

MelCancerVac is an immunotherapeutic treatment used in the treatment of colorectal cancer. It uses the patient´s own dendritic cells – critical components of the immune system – and loads them with tumor antigens from the lysate of a specifically selected melanoma cell line. The ability of the dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit Biotech.”

Read the full article here.

[January 12–15 2015] J.P. Morgan 33rd Annual Healthcare Conference

DanDrit Biotech will attend the J.P. Morgan 33rd Annual Healthcare Conference on January 12, 2015 – January 15, 2015 in San Francisco, CA, USA. Dr. Eric Leire, CEO will be available for meetings and can be reached on +1 (646) 460 4077 (US) and +45 27582457 (DK) or epl@dandrit.com.

[December 22] News Regarding MyTomorrows and Phase III Trials

To the shareholders of DanDrit Biotech USA, Inc.

DanDrit have now received the required permissions to allow initiation of MyTomorrows’ marketing of the DanDrit vaccine. Initially, this means that the DanDrit vaccine, latest during January 2015, will appear on MyTomorrows’ webpage.

Furthermore, DanDrit has received approval allowing us to start the production of our vaccine on a larger scale (Manufacturing of Vaccine under GMP conditions), which was a prerequisite for our ability to deliver vaccines to both the MyTomorrows projects and our phase III trials.

DanDrit’s partner in the phase III trials have identified the hospitals who will deliver the patients to the trials and is in the process of receiving the approval of relevant authorities. The current expectation is that the first phase III patients can receive the vaccine in April 2015.

[December 11] DanDrit inc Has Been Upgraded to the OTCQB Marketplace on December 11, 2014


DanDrit will be represented at numerous conferences this year:

[May 21] “4th Annual Outsourcing in Clinical Trials Europe 2014”

DanDrit CEO Eric Leire will speak at the “4th Annual Outsourcing in Clinical Trials Europe 2014” in Belgium on Wednesday May 21th, from 10:00 to 10:30 AM.

Find out more here.

[June 2–5] “Jefferies 2014 Global Healthcare Conference”

DanDrit will attend the “Jefferies 2014 Global Healthcare Conference” June 2–5 in New York City.

The agenda of the conference is available here.

[September 15–16] The “SMi Group’s 3rd Annual Conference on Cancer Vaccines”

Eric Leire will also speak at the “SMi Group’s 3rd Annual Conference on Cancer Vaccines” held September 15–16 in London.

Details of last year’s event can be found here.

DanDrit is one of the world’s leaders in development of dendritic cell vaccines

DanDrit’s lead compound, MelCancerVac® (MCV), an allogenic dendritic cell vaccine, has successfully completed Phase II for the treatment of advanced colorectal cancer and non-small cell-lung cancer (NSCLC).

DanDrit now takes MCV into an international multi-centre double-blind comparative Phase III clinical trial with advanced colorectal cancer patients.

Scientific Background

Our expertise in producing dendritic cells from patient blood is combined with conventional production methods to make new and advanced vaccines for cancer patients.

The science behind dendritic cells was the subject of the 2011 Nobel Prize of Medicine.

Read more

Company Profile

DanDrit Biotech USA is a US based clinical-stage oncology company developing new approaches to leverage the immune system to fight cancers and infectious diseases. Our vision is to radically improve outcomes for patients with unmet needs in HIV/AIDS and oncology. Our intent is to develop transformative, multi-indication, platform drugs that harness the power of immunotherapy and change the standards of care of AIDS and cancer. We will expedite programs to market through strategic development and leveraging enhanced FDA programs and corporate partnerships.

Read More